Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

214

Citations

18

References

2011

Year

Jonathan A. Ledermann, Allan Hackshaw, Stan Kaye, Gordon C. Jayson, Hani Gabra, Iain A. McNeish, Helena Earl, Timothy Perren, Martin Gore, Mojca Persic,

Journal of Clinical Oncology

Abstract

BIBF 1120 is well tolerated and associated with a potential improvement in PFS. The observed treatment effect is sufficient to justify further study within a large phase III trial.

References

	Year	Citations

Page 1